TY - JOUR
T1 - Target profiling of an antimetastatic RAPTA agent by chemical proteomics
T2 - relevance to the mode of action
AU - Babak, Maria V.
AU - Meier, Samuel M.
AU - Huber, Kilian V. M.
AU - Reynisson, Jóhannes
AU - Legin, Anton A.
AU - Jakupec, Michael A.
AU - Roller, Alexander
AU - Stukalov, Alexey
AU - Gridling, Manuela
AU - Bennett, Keiryn L.
AU - Colinge, Jacques
AU - Berger, Walter
AU - Dyson, Paul J.
AU - Superti-Furga, Giulio
AU - Keppler, Bernhard K.
AU - Hartinger, Christian G.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - The clinical development of anticancer metallodrugs is often hindered by the elusive nature of their molecular targets. To identify the molecular targets of an antimetastatic ruthenium organometallic complex based on 1,3,5-triaza-7-phosphaadamantane (RAPTA), we employed a chemical proteomic approach. The approach combines the design of an affinity probe featuring the pharmacophore with mass-spectrometry-based analysis of interacting proteins found in cancer cell lysates. The comparison of data sets obtained for cell lysates from cancer cells before and after treatment with a competitive binder suggests that RAPTA interacts with a number of cancer-related proteins, which may be responsible for the antiangiogenic and antimetastatic activity of RAPTA complexes. Notably, the proteins identified include the cytokines midkine, pleiotrophin and fibroblast growth factor-binding protein 3. We also detected guanine nucleotide-binding protein-like 3 and FAM32A, which is in line with the hypothesis that the antiproliferative activity of RAPTA compounds is due to induction of a G2/M arrest and histone proteins identified earlier as potential targets. This journal is
AB - The clinical development of anticancer metallodrugs is often hindered by the elusive nature of their molecular targets. To identify the molecular targets of an antimetastatic ruthenium organometallic complex based on 1,3,5-triaza-7-phosphaadamantane (RAPTA), we employed a chemical proteomic approach. The approach combines the design of an affinity probe featuring the pharmacophore with mass-spectrometry-based analysis of interacting proteins found in cancer cell lysates. The comparison of data sets obtained for cell lysates from cancer cells before and after treatment with a competitive binder suggests that RAPTA interacts with a number of cancer-related proteins, which may be responsible for the antiangiogenic and antimetastatic activity of RAPTA complexes. Notably, the proteins identified include the cytokines midkine, pleiotrophin and fibroblast growth factor-binding protein 3. We also detected guanine nucleotide-binding protein-like 3 and FAM32A, which is in line with the hypothesis that the antiproliferative activity of RAPTA compounds is due to induction of a G2/M arrest and histone proteins identified earlier as potential targets. This journal is
UR - http://www.scopus.com/inward/record.url?scp=84924942242&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-84924942242&origin=recordpage
U2 - 10.1039/c4sc03905j
DO - 10.1039/c4sc03905j
M3 - RGC 21 - Publication in refereed journal
C2 - 29308157
SN - 2041-6520
VL - 6
SP - 2449
EP - 2456
JO - Chemical Science
JF - Chemical Science
IS - 4
ER -
